Aardvark Therapeutics, Inc. (AARD)

The past six months have seen significant events impacting Aardvark Therapeutics' stock price. The voluntary pause of the Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome due to cardiac observations led to a substantial stock price drop. The company reported increased net losses and pauses of multiple trials, resulting in a negative market reaction. Aardvark Therapeutics announced the establishment of a new U.S. subsidiary to advance its dermatology pipeline and leadership appointments. The company announced FDA submission and IRB approval of an amended trial protocol for ARD-101. The stock jumped 23% in a week, benefiting individual investors. Aardvark Therapeutics reported Third Quarter 2025 financial results and pipeline updates, including alignment with the FDA to reduce the minimum age of eligibility for the HERO trial and new preclinical data for ARD-201. As of April 6, 2026, the stock price was $4.13, with a market capitalization of $90.1 million, and has lost 54.0% over the past 12 months.

Based on the available information, there is no explicit indication of demand seasonality for Aardvark Therapeutics' products and services.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics that activate innate homeostatic pathways to treat metabolic diseases, especially those associated with hunger. Their lead product candidate, ARD-101, is in Phase 3 clinical development for hyperphagia associated with Prader-Willi Syndrome and is also being investigated for hypothalamic obesity. The company is also developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, and WE-868, a novel small molecule described as an isoflavonoid modulator of oxidative metabolism.

Aardvark Therapeutics, Inc. is headquartered in San Diego, California, United States.

Aardvark Therapeutics' brand reputation has been negatively impacted by the voluntary pause of its Phase 3 HERO trial due to cardiac safety signals, leading to a stock price drop and investigations by shareholder rights firms. Prior to this, the company had a consensus rating of "Moderate Buy" from analysts, but the recent trial pause has overshadowed these positive sentiments.

Aardvark Therapeutics, Inc. has a significant institutional ownership presence, with major shareholders including Decheng Capital LLC, Citadel Advisors Llc, and BlackRock, Inc. Private equity firms hold a 28% stake, hedge funds control 6.2% of the shares, and the general public owns 32%. Tien-Li Lee, the company's founder and CEO, is also a significant individual shareholder.